Disposition of 5653 shares by Lake Ryan David of Lifecore Biomedical at 7.15 subject to Rule 16b-3
| LFCR Stock | 7.62 0.96 14.41% |
Slightly above 62% of all Lifecore Biomedical's retail investors are looking to take a long position. The analysis of the overall investor sentiment regarding Lifecore Biomedical suggests that some traders are interested. Lifecore Biomedical's investing sentiment overview a quick insight into current market opportunities from investing in Lifecore Biomedical. Many technical investors use Lifecore Biomedical stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Lifecore |
Filed transaction by Lifecore Biomedical Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Lifecore Biomedical's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Lifecore Biomedical's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Lifecore Biomedical Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Lifecore Biomedical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Lifecore Biomedical Fundamental Analysis
We analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Lifecore Biomedical is rated fifth overall in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Lifecore Biomedical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lifecore Biomedical stock to make a market-neutral strategy. Peer analysis of Lifecore Biomedical could also be used in its relative valuation, which is a method of valuing Lifecore Biomedical by comparing valuation metrics with similar companies.
Peers
Lifecore Biomedical Related Equities
| LFCR | Lifecore Biomedical | 14.41 | ||||
| RGC | Regencell Bioscience | 7.26 | ||||
| COLL | Collegium Pharmaceutical | 3.07 | ||||
| ANIP | ANI Pharmaceuticals | 0.11 | ||||
| PAHC | Phibro Animal | 1.01 | ||||
| PROC | Procaps Group | 3.43 | ||||
| PTPI | Petros Pharmaceuticals | 14.89 |
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.